Dr. Steven Phillips, MD debunks The Lancet's newest hit piece on HCQ
https://twitter.com/StevePhillipsMD/status/1263899565654265857
Another poorly designed interpretation of a #HCQ data set for #COVID19. A larger poorly designed "trial" only leads to larger erroneous conclusions. For analysis, see the thread
Steven Phillips, MD
@StevePhillipsMD
·
May 23
The authors provide almost no data to assess disease severity at baseline between groups. They rely on qSOFA which in a study in Annals of Intensive Care, was found to be "…not appropriate to identify Covid-19 patients to have poor outcomes…" 👇
Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA
ncbi.nlm.nih.gov
Steven Phillips, MD
@StevePhillipsMD
·
May 23
And they don't say who got what other antiviral, grouping 3 different ones together. Big confounders. Except anyone who took remdesivir was excluded from the analysis. Why? Don't want to risk it being associated with a bad outcome in a faulty study?
Steven Phillips, MD
@StevePhillipsMD
·
May 23
I agree with one thing the authors said: "Randomized clinical trials will be required before any conclusion can be reached regarding benefit or harm of these agents in COVID-19 patients."
Actually, #HCQ RCT's have been done & they show benefits, but we need more of them.